The ICs—PD-L1, Indoleamine 2, 3-Dioxygenase (IDO) and V-set domain-containing T-cell activation inhibitor 1 (B7H4)—are known to potentially be expressed in cancer cells with the capability to inhibit immune responses by interaction with immune cells [2,8,9]. The gene discussed is VTCN1; the disease is cancer.